Unveiling the anti-inflammatory potential of 11β,13-dihydrolactucin for application in inflammatory bowel disease management

Funding Information: This project received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no. 760891 (CHIC). iNOVA4Health Research Unit (UIDB/04462/2020 and UIDP/04462/2020), which is cofunded by Funda\u00E7\u00E3o para a Ci\u00EAncia e Tecnologia (FCT)/Minist\u00E9rio da Ci\u00EAncia e do Ensino Superior (MCES) through National Funds and by FEDER under the PT2020 Partnership Agreement is acknowledged. Zebrafish were reproduced and maintained by the CEDOC Fish Facility, supported by Congento LISBOA-01-0145-FEDER-022170, co-financed by FCT/MCES and Lisboa2020, under the PORTUGAL2020 agreement (European Regional Development Fund). The authors also acknowledge the support from the Associate Laboratories LS4FUTURE (LA/P/0087/2020). C. L. C. and A. J. acknowledge FCT/MCES for the funding grant PTDC/BTM-SAL/29377/2017. M. S. M. and A. T. S. also acknowledge the financial support from FCT/MCTES for their individual grants SFRH/BD/145551/2019 and CEECIND/04801/2017, respectively. A. J. and C. N. S. acknowledge the European Commission (grant number 101060346). A. G. S. acknowledges the grant 22030/PI/22 funded by the Programa Regional de Fomento de la Investigaci\u00F3n Cient\u00EDfica y T\u00E9cnica (Plan de Actuaci\u00F3n 2022) de la Fundaci\u00F3n S\u00E9neca-Agencia de Ciencia y Tecnolog\u00EDa de la Regi\u00F3n de Murcia (Murcia, Spain). The authors would like to acknowledge the support from the CEDOC Fish and Microscopy facilities. Publisher Copyright: © 2024 The Royal Society of Chemistry.